Immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD1) have modest clinical activity as monotherapy in HCC but may be more effective in combination with other therapeutic agents, including anti-angiogenic therapies. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.